Myriad Genetics, Inc. (MYGN) Tops Q1 EPS by 4c; Boosts FY13 Outlook
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- S&P 500, Nasdaq close lower, dragged by Alphabet and megacap tech; focus on Iran
- Oil settles down more 3% after US-Iran talks signal easing supply risks
- Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
- Alan Greenspan, influential former Federal Reserve chair, dies at 100
- Buy gold stocks as valuations are cheap amid macro tension: BofA
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- 'Equal and opposite': BTIG's Krinsky sees sharp reversal ahead for chip stocks
Jefferies Raises Numbers on Myriad Genetics (MYGN)
November 6, 2012 12:54 PM ESTJefferies maintained a Buy rating on Myriad Genetics (NASDAQ: MYGN) and raised its price target to $33.00 (from $31.00). Myriad recently reported earnings that were ahead of consensus, and as a result analysts raised EPS estimates on the diagnostics company.
"We expect... More
